bio reports - Robuta Search

https://www.globenewswire.com/news-release/2025/05/15/3082173/0/en/GRI-Bio-Reports-First-Quarter-2025-Financial-Results-and-Confirms-GRI-0621-Phase-2a-IPF-Trial-on-Track-for-6-Week-Interim-Data-in-Q2-2025-and-Topline-Data-in-Q3-2025.html GRI Bio Reports First Quarter 2025 Financial Results and Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis... bio reports first quarter financial results gri 2025 https://www.financialcontent.com/article/gnwcq-2026-5-7-climb-bio-reports-first-quarter-2026-financial-results-and-provides-business-updates Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates |... Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development bio reports first quarter https://www.globenewswire.com/news-release/2025/07/18/3118168/0/en/Vor-Bio-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of... bio reports nasdaq listing vor inducement grant https://investingnews.com/adicet-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635/ Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635 | INN Sep 30, 2025 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune... bio reports nasdaq listing inducement grant https://finviz.com/news/343874/korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4 Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Stock screener for investors and traders, financial visualizations. bio reports https://www.businesswire.com/news/home/20240628376872/en/Adicet-Bio-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635c4 Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune dis... bio reports https://www.globenewswire.com/news-release/2025/03/20/3046117/0/en/Barinthus-Bio-Reports-Full-Year-2024-Financial-Results-and-Updates-on-Corporate-Developments.html Barinthus Bio Reports Full Year 2024 Financial Results and Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially... bio reports full year financial results barinthus 2024 https://www.businesswire.com/news/home/20250507914974/en/Nuvation-Bio-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for ... nuvation bio first quarter https://www.business-standard.com/amp/markets/capital-market-news/boston-bio-systems-reports-standalone-net-loss-of-rs-0-01-crore-in-the-september-2024-quarter-124111501031_1.html Boston Bio Systems reports standalone net loss of Rs 0.01 crore in the September 2024 quarter |... https://www.biospace.com/tela-bio-reports-strong-third-quarter-2021-revenues-reflecting-continued-growth-driven-by-increased-demand TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased... Nov 11, 2021 - TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to... https://www.biospace.com/gri-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update - BioSpace May 13, 2024 - GRI Bio, Inc. today reported its financial results for the first quarter ended March 31, 2024 and provided a corporate update.